Abstract
The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency. Thirty hypertensive CKD patients were randomly assigned to receive telmisartan 40 mg (n=15) or amlodipine 5 mg (n=15) once daily for 12 months. Changes in blood pressure, serum creatinine, 24-h creatinine clearance (Ccr), proteinuria, brachial-ankle pulse wave velocity (baPWV), intima-media thickness (IMT), plasma interleukin-6 (IL-6), plasma matrix metalloproteinase (MMP)-9 and lipid profiles were monitored in all patients. Before treatment, there were no significant differences in these parameters between the telmisartan and amlodipine groups. Over the 12 month observation period, blood pressure decreased equally in both groups. However, serum creatinine, proteinuria, baPWV, IMT, plasma levels of IL-6 and MMP-9 and total cholesterol decreased and 24-h Ccr increased more strikingly in the telmisartan group than the amlodipine group. These data suggest that telmisartan is more effective than amlodipine for protecting renovascular functions, and potentially for ameliorating atherosclerosis, in hypertensive CKD patients with moderate renal insufficiency.
Similar content being viewed by others
Article PDF
References
Strozecki P, Kozlowski M, Grajewska M, et al: Cardiovascular system in patients in different stages of chronic kidney disease. Pol Merkur Lekarski 2006; 122: 125–131.
Dogra G, Irish A, Chan D, Watts G : Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006; 48: 926–934.
Wang MC, Tsai WC, Chen JY, Huang JJ : Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494–501.
Preston E, Ellis MR, Kulinskaya E, Davies AH, Brown EA : Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 2005; 46: 856–862.
Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD : Relationship between circulating matrix proteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006; 366: 243–248.
Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM : Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125–2131.
Morimoto S, Yano Y, Maki K, Sawada K : Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567–572.
Imayama I, Ichiki T, Inanaga K, et al: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator−activated receptor gamma. Cardiovasc Res 2006; 72: 184–190.
Rysava R, Tesar V, Merta M, for the Czech Group for the Study of Glomerulonephritis: Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit 2005; 10: 207–213.
Kojima S, Shida M, Yokoyama H : Comparison between cilnidipine and amlodipine besilate with repeat to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379–385.
Gashti CN, Bakris GL : The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 2004; 13: 155–161.
Imakiire T, Kikuchi Y, Yamada M, et al: Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertens Res 2007; 30: 635–642.
Lentine K, Wrone EM : New insights into intake and progression of renal disease. Curr Opin Hypertens 2004; 13: 307–312.
Nakamura T, Kawagoe Y, Matsuda T, et al: Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004; 27: 121–126.
Nakamura T, Matsuda T, Kawagoe Y, et al: Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382–1386.
Maeda N, Sawayama Y, Tatsukawa M, Shimizu C, Kashiwagi S, Hayashi J : Chlamydia pneumoniae seropositivity and early carotid atherosclerosis in a suburban Japanese population. Atherosclerosis 2002; 164: 313–319.
Fujimoto N, Hosokawa N, Iwata K, Shinza T, Okada Y, Hayakawa T : A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994; 231: 79–88.
Nakamura T, Ushiyama C, Suzuki S, Ebihara I, Shimada N, Koide H : Evaluation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-9 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol 2000; 20: 32–36.
Weir MR : Progressive renal and cardiovascular disease: optimal treatment stratigies. Kidney Int 2002; 62: 1482–1492.
Schieppatti A, Remuzzi G : The future of renoprotection. Frustrations and promises. Kidney Int 2003; 64: 1974–1985.
Yamagishi S, Takeuchi M : Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma−inducing property. Med Hypotheses 2005; 64: 476–478.
Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442–3452.
Ruster C, Wolf G : Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985–2990.
Sharma AM, Hollander A, Koster J, Efficacy and Safety in Patients with Renal Impairment: Treated with Telmisartan (ESPRIT) Study Group: Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250–257.
Uchida M, Nakama Y, Kaihara M, et al: Practical efficacy of telmisartan for decreasing home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
Terpstra WF, May JF, Smit AJ, Graeff PA, Meyboom-de Jong B, Crijns MJ : Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004; 22: 1309–1316.
Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M : Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006; 20: 787–794.
Rajzer M, Klocek M, Kawecka-Jaszcz K : Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16: 439–444.
Caird J, Napoli C, Taggart C, Farrell M, Bouchier-Hayes D : Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic cerebral aneurysms. Eur J Neurol 2006; 13: 1098–1105.
Nakamura T, Matsusa T, Suzuki Y, Ueda Y, Koide H : Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J 2003; 49: 430–434.
Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K : Matrix metalloproteinase expression in the coronary circulation induced by coronary angiography. Atherosclerosis 2002; 161: 185–192.
Yoshimura Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimada M : Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinase-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 969–975.
Lee WY, Allison MA, Kim DJ, Song CH, Barrett-Connor E : Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol 2007; 99: 99–102.
Derwa A, Peeters P, Vanholder R : Calcium channel blockers in the prevention of end stage renal disease: a review. Acta Clin Belg 2004; 59: 44–56.
Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G : Targeting albumin excretion rate in the treatment of the hypertensive diabetic patients with renal disease. J Am Soc Nephrol 2005; 16: ( Suppl 1): S42–S47.
Kojima S, Shida M, Yokoyama H : Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal disease. Hypertens Res 2004; 27: 379–385.
Ishimitsu T, Kameda T, Akashiba A, et al: Efonidipine reduces proteiuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621–626.
Bezerra DG, Pires KM, Mandarim-de-Lacerda CA : Amlodipine preserves the glomerular number in spontaneously hypertensive rats. J Cell Mol Med 2005; 9: 966–971.
Ichihara A, Kaneshiro Y, Sakoda M, Takemitsu T, Itoh H : Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol 2007; 49: 161–166.
Cupisti A, Rizza GM, D'Alessandro C, Morelli E, Barsotti G : Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003; 57: 169–172.
Weinbergova O, Metelka R, Vymetal J, Konecny K, Kosatikova Z : Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Papers 2004; 148: 69–73.
Aranda P, Segura J, Ruilope LM, et al: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46: 1074–1079.
Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R : Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457–464.
Inoue T, Morooka T, Moroe K, Ikeda H, Node K : Effect of telmisartan on cholesterol levels in patients with hypertension—Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007; 39: 372–376.
Mychka VB, Duishvili DE, Mamyrbueva KM, Masenko VP, Chazova IE : The role of telmisartan in the treatment of metabolic syndrome. Ter Arkh 2006; 78: 63–66.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakamura, T., Inoue, T., Suzuki, T. et al. Comparison of Renal and Vascular Protective Effects between Telmisartan and Amlodipine in Hypertensive Patients with Chronic Kidney Disease with Mild Renal Insufficiency. Hypertens Res 31, 841–850 (2008). https://doi.org/10.1291/hypres.31.841
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.841
Keywords
This article is cited by
-
Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up
Scientific Reports (2021)
-
Dihydropyridine calcium channel blockers and renal disease
Hypertension Research (2017)
-
The impact of angiotensin receptor blockers on arterial stiffness: a meta-analysis
Hypertension Research (2015)
-
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials
Hypertension Research (2013)
-
Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes
Cardiovascular Diabetology (2012)